Stock screenerAll disclosures →
EDGAR →
ADPT
Conviction 77HealthcareScan · Thu, Jun 25, 2026ADPT$20.23+4.60%
ResistanceSupportVol 14Insider sell2
2
2
2
Vol MA14 4.31M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Adaptive Biotechnologies CorpBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.adaptivebiotech.com ↗
Price20.23
Change+4.60%
Gap+1.37%
Rel volume1.58×
Avg volume3.7M
Avg $ vol64.73M
SMA 2017.12
SMA 5015.19
SMA 20015.57
Price vs 50+33.21%
Price vs 200+29.89%
MA stackmixed
50/200 cross—
Supertrendup · 16.25
RSI (14)71
MACD hist0.18
MACD crossbull · 1d
Stoch %K / %D92 / 78
ADX (14)38
+DI / −DI34 / 9
RSI divergenceBearish
MACD divergenceBearish
ATR %+6.01%
ADR %7.39%
52w high20.46
52w low10.24
From 52w high-1.12%
Above 52w low+97.56%
New 52w highNo
SqueezeOff
Bollinger width31.13%
%B1.08
Donchian pos94.13%
Donchian high20.63
Donchian low13.81
AVWAP (52w high)15.89
vs AVWAP high+27.31%
AVWAP (52w low)15.34
vs AVWAP low+31.86%
OBV trendFlat
Chaikin MF (20)0.07
Today vs 20d1.58×
Avg vol (14d)4.31M
Avg vol (20d)3.7M
Avg $ vol (20d)64.73M
Market cap3.24B
RS 3m (vs SPY)+26.88%
RS 6m (vs SPY)+6.03%
RS line new highYes
Trend template7/8
Technical rank89.7
1 week+20.56%
1 month+43.17%
3 months+42.97%
6 months+16.20%
1 year+89.95%
YTD+27.15%
P/E-54.42
P/B14.97
P/S11.69
P/FCF-66.15
EPS-0.3900
Div yield—
ROE-27.50%
ROA-11.76%
Debt/Eq0.60
Current3.35
EV/EBITDA-80.02
Gross margin—
Net margin-21.48%
Rev growth54.77%
EPS growth62.69%
Price target20.17
Target upside-0.30%
Analyst ratingBuy
Institutional102.18%
Ent. value3.29B
Revenue70.87M
Net income-20.03M
Gross profit—
Free cash flow-48.95M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out160.04M
Employees624
ListedThu, Jun 27, 2019
Free float113.41M
Float %74.3%
Short interest8.24M
Days to cover5.1d
Short volume37.1%
Squeeze score48 / 100
Next earningsTue, Aug 4, 2026 (40d)
EPS forecast−$0.13 · 4 est
Last EPS vs est−$0.13 vs −$0.16
Last surprise+18.8% beat
Setup gradeA
Conviction77 / 100
Pattern quality—
Tech rank89.7 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance18.91
Support12.74
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in ADPT
No recent disclosed trades by Congress in ADPT. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ADPT · 4 buys · 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
ROBINS HARLAN S Chief Scientific Officer · Common Stock · 2026-06-16 | Sell | 6.16K | $111K | 2026-06-16 | 2026-06-17 |
ROBINS HARLAN S Chief Scientific Officer · Common Stock · 2026-06-15 | Sell | 100K | $1.7M | 2026-06-15 | 2026-06-17 |
LO FRANCIS Chief People Officer · Stock Option (right to buy) · 2026-06-04 | Exercise | 2.01K | $0 | 2026-06-04 | 2026-06-08 |
LO FRANCIS Chief People Officer · Common Stock · 2026-06-04 | Exercise | 2.01K | $17K | 2026-06-04 | 2026-06-08 |
LO FRANCIS Chief People Officer · Stock Option (right to buy) · 2026-06-04 | Exercise | 2.34K | $0 | 2026-06-04 | 2026-06-08 |
LO FRANCIS Chief People Officer · Common Stock · 2026-06-04 | Exercise | 9.38K | $76K | 2026-06-04 | 2026-06-08 |
LO FRANCIS Chief People Officer · Common Stock · 2026-06-04 | Exercise | 2.34K | $9K | 2026-06-04 | 2026-06-08 |
LO FRANCIS Chief People Officer · Stock Option (right to buy) · 2026-06-04 | Exercise | 9.38K | $0 | 2026-06-04 | 2026-06-08 |
BOBULSKY SUSAN Chief Commercial Officer, MRD · Common Stock · 2026-06-04 | Sell | 11K | $198K | 2026-06-04 | 2026-06-08 |
LO FRANCIS Chief People Officer · Common Stock · 2026-06-04 | Exercise | 5.79K | $70K | 2026-06-04 | 2026-06-08 |
SEC filings
EDGAR filings in ADPT · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.